Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 15 January 1993:
Vol. 259. no. 5093, pp. 373 - 377
DOI: 10.1126/science.8420006
Prev | Table of Contents | Next

Articles

Science, Vol 259, Issue 5093, 373-377
Copyright © 1993 by American Association for the Advancement of Science

articles

Blood-brain barrier penetration and in vivo activity of an NGF conjugate

PM Friden, LR Walus, P Watson, Doctrow SR, JW Kozarich, C Backman, H Bergman, B Hoffer, F Bloom, and AC Granholm

Alkermes, Inc., Cambridge, MA 02139.

Nerve growth factor (NGF) is essential for the survival of both peripheral ganglion cells and central cholinergic neurons of the basal forebrain. The accelerated loss of central cholinergic neurons during Alzheimer's disease may be a determinant of dementia in these patients and may therefore suggest a therapeutic role for NGF. However, NGF does not significantly penetrate the blood-brain barrier, which makes its clinical utility dependent on invasive neurosurgical procedures. When conjugated to an antibody to the transferrin receptor, however, NGF crossed the blood-brain barrier after peripheral injection. This conjugated NGF increased the survival of both cholinergic and noncholinergic neurons of the medial septal nucleus that had been transplanted into the anterior chamber of the rat eye. This approach may prove useful for the treatment of Alzheimer's disease and other neurological disorders that are amenable to treatment by proteins that do not readily cross the blood-brain barrier.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
From the Cover: Targeted delivery of proteins across the blood-brain barrier.
B. J. Spencer and I. M. Verma (2007)
PNAS 104, 7594-7599
   Abstract »    Full Text »    PDF »
Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen.
N. A. Ponomarenko, O. M. Durova, I. I. Vorobiev, A. A. Belogurov Jr., I. N. Kurkova, A. G. Petrenko, G. B. Telegin, S. V. Suchkov, S. L. Kiselev, M. A. Lagarkova, et al. (2006)
PNAS 103, 281-286
   Abstract »    Full Text »    PDF »
The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery.
D. R. Groothuis (2000)
Neuro-oncol 2, 45-59
   Abstract »    PDF »
Neurotransplantation of magnetically labeled oligodendrocyte progenitors: Magnetic resonance tracking of cell migration and myelination.
J. W. M. Bulte, S.-C. Zhang, P. van Gelderen, V. Herynek, E. K. Jordan, I. D. Duncan, and J. A. Frank (1999)
PNAS 96, 15256-15261
   Abstract »    Full Text »    PDF »
Evaluation of Effect of Charge and Lipid Coating on Ability of 60-nm Nanoparticles to Cross an In Vitro Model of the Blood-Brain Barrier.
L. Fenart, A. Casanova, B. Dehouck, C. Duhem, S. Slupek, R. Cecchelli, and D. Betbeder (1999)
J. Pharmacol. Exp. Ther. 291, 1017-1022
   Abstract »    Full Text »
An Antibody-Avidin Fusion Protein Specific for the Transferrin Receptor Serves as a Delivery Vehicle for Effective Brain Targeting: Initial Applications in Anti-HIV Antisense Drug Delivery to the Brain.
M. L. Penichet, Y.-S. Kang, W. M. Pardridge, S. L. Morrison, and S.-U. Shin (1999)
J. Immunol. 163, 4421-4426
   Abstract »    Full Text »    PDF »
Cholecystokinin-8 protects central cholinergic neurons against fimbria-fornix lesion through the up-regulation of nerve growth factor synthesis.
P. Tirassa, L. Aloe, C. Stenfors, P. Turrini, and T. Lundeberg (1999)
PNAS 96, 6473-6477
   Abstract »    Full Text »    PDF »
Herpes Simplex Virus Type 1 Vector-Mediated Expression of Nerve Growth Factor Protects Dorsal Root Ganglion Neurons from Peroxide Toxicity.
W. F. Goins, K. A. Lee, J. D. Cavalcoli, M. E. O'Malley, S. T. DeKosky, D. J. Fink, and J. C. Glorioso (1999)
J. Virol. 73, 519-532
   Abstract »    Full Text »    PDF »
Review : Gene Therapy: Applications to the Neurosciences and to Neurological Disease.
M. H. Tuszynski (1998)
Neuroscientist 4, 398-407
   Abstract »    PDF »
Role of sphingolipid-mediated cell death in neurodegenerative diseases.
T. Ariga, W. D. Jarvis, and R. K. Yu (1998)
J. Lipid Res. 39, 1-16
   Abstract »    Full Text »
A New Function for the LDL Receptor: Transcytosis of LDL across the Blood-Brain Barrier.
B. Dehouck, L. Fenart, M.-P. Dehouck, A. Pierce, G. Torpier, and R. Cecchelli (1997)
J. Cell Biol. 138, 877-889
   Abstract »    Full Text »    PDF »
Systemic Administration of a Nerve Growth Factor Conjugate Reverses Age-Related Cognitive Dysfunction and Prevents Cholinergic Neuron Atrophy.
C. Backman, G. M. Rose, B. J. Hoffer, M. A. Henry, R. T. Bartus, P. Friden, and A.-C. Granholm (1996)
J. Neurosci. 16, 5437-5442
   Abstract »    Full Text »    PDF »
Low Levels of Nerve Growth Factor in Cerebrospinal Fluid of Children With Rett Syndrome.
R. Lappalainen, D. Lindholm, and R. Riikonen (1996)
J Child Neurol 11, 296-300
   Abstract »    PDF »
Gene Therapy for Neurologic Disease.
S. T. Suhr and F. H. Gage (1993)
Arch Neurol 50, 1252-1268
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)